Literature DB >> 29493401

Bone marrow-derived mesenchymal stem cells promote cell proliferation of multiple myeloma through inhibiting T cell immune responses via PD-1/PD-L1 pathway.

Dandan Chen1, Ping Tang1, Linxiang Liu1, Fang Wang1, Haizhou Xing1, Ling Sun1, Zhongxing Jiang1.   

Abstract

OBJECTIVES: This study aims to explore the effect of bone marrow mesenchymal stem cells (BMSCs) on multiple myeloma (MM) development and the underlying mechanism.
MATERIALS AND METHODS: BMSCs from C57BL/6 J mice were isolated and the third passage was used for subsequent experiments. Additionally, a series of in vitro transwell coculture assays were performed to explore the effects of BMSCs on the proliferation of MM cells 5TGM1 and CD4+ T cells. Furthermore, a 5TGM1-induced MM mice model was established. Moreover, PD-L1 shRNA was transfected into BMSCs to investigate whether PD-1/PD-L1 pathway involved in BMSCs-mediated regulation of T cells and MM growth.
RESULTS: Data revealed that BMSCs significantly promoted 5TGM1 proliferation in a dose-dependent manner. Furthermore, BMSCs administration exerted stimulatory effects on MM development in terms of shortening the mouse survival rate, promoting tumor growth, and enhancing inflammatory infiltration in the MM model mice. Moreover, BMSCs decreased the percentage of Th1 and Th17 cells, whereas increased that of Th2 and Treg cells. Their corresponding cytokines of these T cell subsets showed similar alteration in the presence of BMSCs. Additionally, BMSCs significantly suppressed CD4+ T cell proliferation. We also found that PD-L1 shRNA inhibited 5TGM1 proliferation likely through activation of CD4+ T cells. Further in vivo experiments confirmed that PD-L1 inhibition attenuated BMSCs-induced MM growth, inflammation infiltration and imbalance of Th1/Th2 and Th17/Treg.
CONCLUSION: In summary, our findings demonstrated that BMSCs promoted cell proliferation of MM through inhibiting T cell immune responses via PD-1/PD-L1 pathway.

Entities:  

Keywords:  5TGM1; CD4+ T cells; Multiple myeloma; PD-1/PD-L1; bone marrow mesenchymal stem cells

Mesh:

Substances:

Year:  2018        PMID: 29493401      PMCID: PMC6056211          DOI: 10.1080/15384101.2018.1442624

Source DB:  PubMed          Journal:  Cell Cycle        ISSN: 1551-4005            Impact factor:   4.534


  57 in total

1.  Mesenchymal stem cells inhibit the formation of cytotoxic T lymphocytes, but not activated cytotoxic T lymphocytes or natural killer cells.

Authors:  Ida Rasmusson; Olle Ringdén; Berit Sundberg; Katarina Le Blanc
Journal:  Transplantation       Date:  2003-10-27       Impact factor: 4.939

Review 2.  Multiple myeloma mesenchymal stem cells: characterization, origin, and tumor-promoting effects.

Authors:  Michaela R Reagan; Irene M Ghobrial
Journal:  Clin Cancer Res       Date:  2011-11-07       Impact factor: 12.531

3.  Targeting PD1-PDL1 immune checkpoint in plasmacytoid dendritic cell interactions with T cells, natural killer cells and multiple myeloma cells.

Authors:  A Ray; D S Das; Y Song; P Richardson; N C Munshi; D Chauhan; K C Anderson
Journal:  Leukemia       Date:  2015-01-30       Impact factor: 11.528

4.  IL-17 plays an important role in the development of experimental autoimmune encephalomyelitis.

Authors:  Yutaka Komiyama; Susumu Nakae; Taizo Matsuki; Aya Nambu; Harumichi Ishigame; Shigeru Kakuta; Katsuko Sudo; Yoichiro Iwakura
Journal:  J Immunol       Date:  2006-07-01       Impact factor: 5.422

Review 5.  Coinhibitory Molecule PD-1 as a Therapeutic Target in the Microenvironment of Multiple Myeloma.

Authors:  Djordje Atanackovic; Tim Luetkens; Sabari Radhakrishnan; Nicolaus Kroger
Journal:  Curr Cancer Drug Targets       Date:  2017       Impact factor: 3.428

Review 6.  PD-1/PD-L1 inhibitors in haematological malignancies: update 2017.

Authors:  Tomas Jelinek; Jana Mihalyova; Michal Kascak; Juraj Duras; Roman Hajek
Journal:  Immunology       Date:  2017-08-04       Impact factor: 7.397

7.  Dual effects of macrophage inflammatory protein-1alpha on osteolysis and tumor burden in the murine 5TGM1 model of myeloma bone disease.

Authors:  Babatunde O Oyajobi; Giovanni Franchin; Paul J Williams; Donna Pulkrabek; Anjana Gupta; Steve Munoz; Barry Grubbs; Ming Zhao; Di Chen; Barbara Sherry; Gregory R Mundy
Journal:  Blood       Date:  2003-03-20       Impact factor: 22.113

8.  B7-H1 blockade augments adoptive T-cell immunotherapy for squamous cell carcinoma.

Authors:  Scott E Strome; Haidong Dong; Hideto Tamura; Stephen G Voss; Dallas B Flies; Koji Tamada; Diva Salomao; John Cheville; Fumiya Hirano; Wei Lin; Jan L Kasperbauer; Karla V Ballman; Lieping Chen
Journal:  Cancer Res       Date:  2003-10-01       Impact factor: 12.701

9.  [Levels of T-Lymphocyte Subsets, IL-17, IL-35 and IFN-γ in Peripheral Blood and Their Clinical Significance in Patients with Multiple Myeloma].

Authors:  Zhao-Juan Xu; Dong Zhao; Fu-Ping Li; Ying-Fang Wang; Hui-Ying Xiao; Xu Wang
Journal:  Zhongguo Shi Yan Xue Ye Xue Za Zhi       Date:  2017-10

10.  Mesenchymal stem cells inhibit multiple myeloma cells via the Fas/Fas ligand pathway.

Authors:  Ikiru Atsuta; Shiyu Liu; Yasuo Miura; Kentaro Akiyama; Chider Chen; Ying An; Songtao Shi; Fa-Ming Chen
Journal:  Stem Cell Res Ther       Date:  2013       Impact factor: 6.832

View more
  15 in total

Review 1.  Mechanisms supporting potential use of bone marrow-derived mesenchymal stem cells in psychocardiology.

Authors:  Jianyang Liu; Lijun Zhang; Meiyan Liu
Journal:  Am J Transl Res       Date:  2019-11-15       Impact factor: 4.060

2.  Endometriosis stromal cells induce bone marrow mesenchymal stem cell differentiation and PD-1 expression through paracrine signaling.

Authors:  Peng Chen; Ramanaiah Mamillapalli; Shutaro Habata; Hugh S Taylor
Journal:  Mol Cell Biochem       Date:  2021-01-11       Impact factor: 3.396

3.  BMSCs improve TNBS-induced colitis in rats by inducing Treg differentiation by expressing PD-L1.

Authors:  Fei Gao; Dandan Cui; Dongmei Zuo; Zhexing Shou; Jia Yang; Ting Yu; Yujin Liu; Si Chu; Feng Zhu; Chunzhu Wei
Journal:  Biotechnol Lett       Date:  2022-10-20       Impact factor: 2.716

4.  In vitro facilitating role of polygonatum sibiricum polysaccharide in osteogenic differentiation of bone marrow mesenchymal stem cells from patients with multiple myeloma.

Authors:  Jianqiang Zhao; Lijie Ma; Zengfeng Ni; Hui Liu
Journal:  Biotechnol Lett       Date:  2021-04-23       Impact factor: 2.461

5.  BMSCs differentiated into neurons, astrocytes and oligodendrocytes alleviated the inflammation and demyelination of EAE mice models.

Authors:  Guo-Yi Liu; Yan Wu; Fan-Yi Kong; Shu Ma; Li-Yan Fu; Jia Geng
Journal:  PLoS One       Date:  2021-05-13       Impact factor: 3.240

6.  Bone marrow-derived mesenchymal stem cells inhibit CD8+ T cell immune responses via PD-1/PD-L1 pathway in multiple myeloma.

Authors:  Z Liu; F Mi; M Han; M Tian; L Deng; N Meng; J Luo; R Fu
Journal:  Clin Exp Immunol       Date:  2021-05-07       Impact factor: 5.732

7.  Bone marrow mesenchymal stem cells improve thymus and spleen function of aging rats through affecting P21/PCNA and suppressing oxidative stress.

Authors:  Zhihong Wang; Yun Lin; Shang Jin; Tiannan Wei; Zhihai Zheng; Weimin Chen
Journal:  Aging (Albany NY)       Date:  2020-06-19       Impact factor: 5.682

Review 8.  Promises and Pitfalls in the Use of PD-1/PD-L1 Inhibitors in Multiple Myeloma.

Authors:  Stefania Oliva; Rossella Troia; Mattia D'Agostino; Mario Boccadoro; Francesca Gay
Journal:  Front Immunol       Date:  2018-11-27       Impact factor: 7.561

Review 9.  Osteoclast Immunosuppressive Effects in Multiple Myeloma: Role of Programmed Cell Death Ligand 1.

Authors:  Yu-Tzu Tai; Shih-Feng Cho; Kenneth C Anderson
Journal:  Front Immunol       Date:  2018-08-10       Impact factor: 7.561

10.  Transcriptome Analysis of Mesenchymal Stem Cells from Multiple Myeloma Patients Reveals Downregulation of Genes Involved in Cell Cycle Progression, Immune Response, and Bone Metabolism.

Authors:  Rodrigo Carlini Fernando; Diego Robles Mazzotti; Hatylas Azevedo; Alex Freire Sandes; Edgar Gil Rizzatti; Mariana Bleker de Oliveira; Veruska Lia Fook Alves; Angela Isabel Pereira Eugênio; Fabrício de Carvalho; Maria Aparecida Dalboni; David Correa Martins; Gisele Wally Braga Colleoni
Journal:  Sci Rep       Date:  2019-01-31       Impact factor: 4.379

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.